Pharmaceutical Business review

University of Oxford to use ExpreS2 technology

The platform, which is stable and non-lytic protein expression, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford.

The solution will also be used by various research teams to meet complex and difficult-to-make proteins.

ExpreS2ion Biotechnologies CEO Charlotte Dyring said ExpreS2ion is happy that the Jenner Institute has taken a Research License for protein expression.

”The ExpreS2 platform has shown to provide a way forward to projects with a need for a robust and fully scalable protein production platform, such as certain challenging recombinant subunit vaccine projects,” Dyring added.